This session will open with a Time=Lives Talk by Casey McPherson, Co-Founder and Chief Innovation Officer, Everlum Bio and Founder and President, To Cure A Rose Foundation, followed by a panel discussion on Building the Clinical Trial Enterprise of the Future.

Clinical trials are a lengthy and expensive phase in the development of new products to treat and prevent disease. While much has been written about the need to streamline the clinical development process, there has been little substantive change. Three areas need urgent attention: The clinical trial enterprise of the future should more closely reflect the social burden of disease, particularly on underrepresented groups; it should more fully embrace the opportunities of digital disruption; and it should eliminate steps that cost money and time without adding value. What can be done to bring about these and other efficiencies? What other changes to clinical trial phase of drug development will be necessary to create a patient-centered health delivery system in the foreseeable future?"

Guest

Casey McPherson
Co-Founder and Chief Innovation Officer, Everlum Bio; Founder and President, To Cure A Rose Foundation

Moderator

Adrian Hernandez
Executive Director, Duke Clinical Research Institute

Speakers

Louis DeGennaro
President and CEO, Leukemia & Lymphoma Society

Eric Lefkofsky
Founder and CEO, Tempus

William Pao
Chief Development Officer and Executive Vice President, Pfizer

Janet Woodcock
Principal Deputy Commissioner, US Food and Drug Administration